Copy Link Print Information

Doxorubicin

(Synonyms: Hydroxydaunorubicin)
698 Cited Publications
Customer Review

Based on 698 publication(s) in Google Scholar

Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy.

For research use only. We do not sell to patients.

  • CAS No.: 23214-92-8
  • Formula: C27H29NO11
  • Molecular Weight:543.52
  • Storage:

    4°C, sealed storage, away from moisture and light

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

  • Doxorubicin Chemical Structure
    Doxorubicin Chemical Structure
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
  • Experimental Validation Results for Doxorubicin
CAS No.: 23214-92-8
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Doxorubicin:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Doxorubicin

More
Customer Validation & Images
IFIn Vivo Efficacy StudyIHCCell Proliferation/Viability AssayWB
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • WB
  • IF
  • WB
  • IHC
  • IF
  • WB
  • WB
  • WB
  • IF
  • WB
  • WB
  • IF

All ADC Payloads Isoforms

More

All Antibiotic Isoforms

More

All Topoisomerase Isoforms

More

All AMPK Isoforms

More

All HIV Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Doxorubicin Chemical Structure
    Doxorubicin Chemical Structure
    1/16
  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 May 9;23(1):83. [Abstract]

    Customer Validation
     Exhausted T-cells (NExT) loaded with Doxorubicin (5–50 nM; 48 h) significantly reduces the viability of SUM159 cells.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2024 May 11:38:384-398. [Abstract]

    Customer Validation
     Doxorubicin hydrochloride (10 μM; 3-5 days) significantly reduces the viability of lung cancer organoid-2 (LCO-2) and LCO-3, while showing no significant effect on LCO-1 viability.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]

    Customer Validation
     The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     SUDHL-4, OCI-Ly3 cells were treated with different concentrations of FKB (Flavokawain B; HY-N2132; 1.25–20 µg/ml) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability (OD value at 490 nm) was measured using the MTS assay. *p < 0.05, #p < 0.01, †p < 0.001, and ‡p < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     Raji, and Jeko-1 cells were treated with different concentrations of FKB (Flavokawain B; HY-N2132; 1.25–20 µg/ml) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability (OD value at 490 nm) was measured using the MTS assay. *p < 0.05, #p < 0.01, †p < 0.001, and ‡p < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     FKB (Flavokawain B; HY-N2132) decelerates lymphoma growth of SUDHL-4 cells in a xenograft animal model in vivo. BALB/c nude mice were subcutaneously inoculated with 5 × 106 SUDHL-4 cells on day 0. Mice were randomly divided into four groups (n = 5 per group) and treatment with vehicle or the corresponding drugs (FKB (HY-N2132; 0.75, 1.5 mg/kg; every four days; IP), or Doxorubicin (HY-15142A; 5 mg/kg; once a week; IP)) was initiated on day 3. The tumor volume was recorded at indicated days. *p < 0.05 and #p < 0.01 versus the control. Tumors were weighed and photographed after removing from each mouse at the end of the experiment (on day 29). *p < 0.05, #p < 0.01, and †p < 0.001 versus the control.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     SUDHL-4 and OCI-Ly3 cells were treated with FKA (Flavokawain A; HY-N2420; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     Raji and Jeko-1 cells were treated with FKA (Flavokawain A; HY-N2420; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     SUDHL-4 and OCI-Ly3 cells were treated with FKC (Flavokawain C; HY-N2445; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

    Customer Validation
     Raji and Jeko-1 cells were treated with FKC (Flavokawain C; HY-N2445; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 23 October 2021.

    Customer Validation
     Cell viability after incubated with free DOX under normoxia and hypoxia at various DOX (Doxorubicin) (0.65-20 μg/mL) concentrations for 24 h determined by MTT assay.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2020 Sep;22(9):1056-1063. [Abstract]

    Customer Validation
     UFMylation of endogenous p53 was analysed by western blot in HCT116 p53+/+ cells depleted of UFL1 or DDRGK1 upon DNA damage induced by doxorubicin (doxo; 1 µM; 24 h) or etoposide (eto; 25 µg ml−1; 12 h).

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887. [Abstract]

    Customer Validation
     Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Representative images of immunofluorescence staining of KRT8 of CM318 and UCH1 cell line.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887. [Abstract]

    Customer Validation
     Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Western blotting analysis and quantification of KRT8 protein expression (normalized to GAPDH expression).

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2019 Jan:130:557-567. [Abstract]

    Customer Validation
     Representative pictures of Live/Dead staining of effects of 7,8-DHF on high dose of Dox-induced cell death and MMP reduction of H9c2 cells.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Sep;23(9):6034-6047. [Abstract]

    Customer Validation
     Effects of YWPC (50 mg/L for 24 h) on DOX (5 μM for 24 h)-induces dissipation of mitochondrial membrane potential measured in H9C2 cells loaded with JC-1 using fluorescence microscopy.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139. [Abstract]

    Customer Validation
     One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2018 Jan 2;128(1):483-499. [Abstract]

    Customer Validation
     Immunoblotting for EZH2 in lysates of immortalized mouse podocytes after treatment with Adriamycin (300 ng/mL) for 48 hours (n=6).

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Sep 19;37(1):232. [Abstract]

    Customer Validation
     Immunoblotting shows that both P-gp protein expression is significantly decreased in 24 h after US exposure in MCF-7/ADR and HEPG2/ADM cells.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nanoscale Res Lett. 2018 Nov 3;13(1):350. [Abstract]

    Customer Validation
     Fluorescence microscopy of images of fixed 4T1-luc2-GFP breast cancer cells treated with Doxorubicin (DOX) after 48-h exposure. Scale bars indicate 100 μm. Blue nuclear stain: DAPI; green (transfected cell line): GFP; red (intrinsic molecular fluorescence): DOX

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 Aug:36:108-116. [Abstract]

    Customer Validation
     PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), CDDP (for 24 h) and Doxorubicin (for 10 h) as indicated, followed by immunoblotting with the antibodies.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;42(3):965-973. [Abstract]

    Customer Validation
     U937 cells are treated with Thapsigargin (TG, 1 μM), NSC 125973 (PTX, 5nM) as well as Doxorubincin (DOX, 1 μM) for 12 hours and the indicated proteins are detected by Western blot.

  • 1/16

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Med. 2016 May;22(5):547-56. [Abstract]

    Customer Validation
     Immunofluorescent staining for α-actinin (ACTN2) and cardiac troponin T (TNNT2) to demonstrate sarcomeric organization in hiPSC–CMs derived from patients who do not experience Doxorubicin–induced cardiotoxicity (DOX) versus those who do experience Doxorubicin-induced cardiotoxicity (DOXTOX) after 24 h treatment with Doxorubicin. Scale bar, 20 µm.

  • Doxorubicin